Title: Vascular Involvement in Cognitive Decline and Dementia: Epidemiologic Evidence from the Rotterdam Study and the Rotterdam Scan Study
Abstract: Annals of the New York Academy of SciencesVolume 903, Issue 1 p. 457-465 Vascular Involvement in Cognitive Decline and Dementia: Epidemiologic Evidence from the Rotterdam Study and the Rotterdam Scan Study MONIQUE M.B. BRETELER, Corresponding Author MONIQUE M.B. BRETELER Department of Epidemiology and Biostatistics, Erasmus Medical Center Rotterdam, 3000 DR Rotterdam, the Netherlands Address for correspondence: Monique M.B. Breteler, M.D., Ph.D., Dept. of Epidemiology & Biostatistics, Erasmus Medical Center Rotterdam, PO Box 1738, 3000 DR Rotterdam, the Netherlands. Tel.: +31 10 408 7489; fax: +31 10 408 9382. email: [email protected]Search for more papers by this author MONIQUE M.B. BRETELER, Corresponding Author MONIQUE M.B. BRETELER Department of Epidemiology and Biostatistics, Erasmus Medical Center Rotterdam, 3000 DR Rotterdam, the Netherlands Address for correspondence: Monique M.B. Breteler, M.D., Ph.D., Dept. of Epidemiology & Biostatistics, Erasmus Medical Center Rotterdam, PO Box 1738, 3000 DR Rotterdam, the Netherlands. Tel.: +31 10 408 7489; fax: +31 10 408 9382. email: [email protected]Search for more papers by this author First published: 30 January 2006 https://doi.org/10.1111/j.1749-6632.2000.tb06399.xCitations: 161Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 Skoog, I., R.N. Kalaria & M.M.B. Breteler. 1999. Vascular factors and Alzheimer's disease. Alzheimer Dis. Assoc. Disord. 13 (Suppl. 3): S106–S114. 2 Breteler, M.M.B. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. In Cerebrovascular Amyloidosis in Alzheimer's Disease and Related Disorders. M.M. Verbeek, H.V. Vinters & R.M. de Waal, Eds. Kluwer Academic Publishers. Dordrecht, the Netherlands. In press. 3 Hofman, A., D.E. Grobbee, P.T.V.M. de Jong, P.T.V.M. & F.A. van den Ouweland. 1991. Determinants of disease and disability in the elderly: the Rotterdam elderly study. Eur. J. Epidemiol. 7: 403–422. 4 Breteler, M.M.B., F.A. van den Ouweland, D.E. Grobbee & A. Hofman. 1992. A community-based study of dementia: the Rotterdam elderly study. Neuroepidemiology 11 (Suppl. 1): 23–28. 5 Ott, A., M.M.B. Breteler, F. van Harskamp, J.J. Claus, T.J.M. van der Cammen, D.E. Grobbee & A. Hofman. 1995. Prevalence of Alzheimer's disease and vascular dementia: association with education: the Rotterdam Study. BMJ 310: 970–973. 6 Ott, A., M.M.B. Breteler, F. van Harskamp, T. Stijnen & A. Hofman. 1998. Incidence and risk of dementia: the Rotterdam Study. Am. J. Epidemiol. 147: 574–580. 7 Breteler, M.M.B., J.C. van Swieten, M.L. Bots, D.E. Grobbee, J.J. Claus, J.H.W. van den Hout, F. van Harskamp, H.L.J. Tanghe, P.T.V.M. de Jong, J. van Gijn & A. Hofman. 1994. Cerebral white matter lesions, vascular risk factors and cognitive function in a population-based study. Neurology 44: 1246–1252. 8 Hofman, A., F. Boomsma, M.A.D.H. Schalekamp & H.A. Valkenburg. 1979. Raised blood pressure and plasma noradrenaline concentrations in teenagers and young adults selected from an open population. BMJ 1: 1536–1538. 9 Breteler, M.M.B., J.J. Claus, D.E. Grobbee & A. Hofman. 1994. Cardiovascular disease and the distribution of cognitive function in an elderly population: the Rotterdam Study. BMJ 308: 1604–1608. 10 Kalmijn, S., L.J. Launer, J. Lindemans, J.L. Bots, A. Hofman & M.M.B. Breteler. 1999. Total homocysteine and cognitive decline in a community-based sample of elderly subjects: the Rotterdam Study. Am. J. Epidemiol. 150: 283–289. 11 Hofman, A., A. Ott, M.M.B. Breteler, M.L. Bots, A.J.C. Slooter, F. van Harskamp, C.M. van Duijn, C. van Broeckhoven & D.E. Grobbee. 1997. Atherosclerosis, apolipoprotein E and the prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 349: 151–154. 12 Slooter, A.J.C., M. Cruts, A. Ott, M.L. Bots, J.C.M. Witteman, A. Hofman, C. van Broeckhoven, M.M.B. Breteler & C.M. van Duijn. 1999. The effect of APOE on dementia is not through atherosclerosis: the Rotterdam Study. Neurology 53: 1593–1595. 13 Ott, A., A.J.C. Slooter, A. Hofman, F. van Harskamp, J.C.M. Witteman, C. van Broeckhoven, C.M. van Duijn & M.M.B. Breteler. 1998. Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study. Lancet 351: 1840–1843. 14 van Duijn, C.M., L.M. Havekes, C. van Broeckhoven, P. de Knijff & A. Hofman. 1995. Apolipoprotein E genotype and association between smoking and early onset Alzheimer's disease. BMJ 310: 627–631. 15 Poirier, J., M.-C. Delisle, R. Quirion et al. 1995. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc. Natl. Acad. Sci. USA 92: 12260–12264. 16 Ott, A., R.P. Stolk, A. Hofman, F. van Harskamp, D.E. Grobbee & M.M.B. Breteler. 1996. Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia 39: 1392–1397. 17 Ott, A., R.P. Stolk, F. van Harskamp, H.A.P. Pols, A. Hofman & M.M.B. Breteler. 1999. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 53: 1937–1942. 18 Ott, A., M.M.B. Breteler, M.C. de Bruyne, F. van Harskamp, D.E. Grobbee & A. Hofman. 1997. Atrial fibrillation and dementia in a population-based study: the Rotterdam Study. Stroke 28: 316–321. 19 Koster, T., F.R. Rosendaal, H. Ronde, E. Briet, J.P. Vandenbroucke & R.M. Bertina. 1993. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 342: 1503–1506. 20 Svensson, P.J. & B. Dahlback. 1994. Resistance to activated protein C as a basis for venous thrombosis. N. Engl. J. Med. 330: 517–522. 21 Bertina, R.M., B.P.C. Koeleman, T. Koster, F.R. Rosendaal, R.J. Dirven, H. de Ronde, P.A. van der Velden & P.H. Reitsma. 1994. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369: 64–67. 22 Kontula, K., A. Ylikorlala, H. Miettinen, A. Vuorio, R. Kauppinen-Mäkelin, L. Hämäläinen, H. Palomaki & M. Kaste. 1995. Arg506Gln factor V mutation in patients with ischemic cerebrovascular disease and survivors of myocardial infarction. Thromb. Haemost. 73: 558–560. 23 Ridker, P.M., C.H. Hennekens, K. Lindpainter, M.J. Stampfer, P.R. Eisenberg & J.P. Miletich. 1995. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men. N. Engl. J. Med. 332: 912–917. 24 Bots, M.L., F. van Kooten, M.M.B. Breteler, P.E. Slagboom, A. Hofman, F. Haverkate, P. Meijer, P.J. Koudstaal, D.E. Grobbee & C. Kluft. 1998. Response to activated protein C in subjects with and without dementia: the Dutch vascular factors in dementia study. Haemostasis 28: 209–215. 25 Bots, M.L., M.M.B. Breteler, F. van Kooten, F. Haverkate, P. Meijer, P.J. Koudstaal, D.E. Grobbee & C. Kluft. 1998. Coagulation and fibrinolysis markers and risk of dementia: the Dutch vascular factors in dementia study. Haemostasis 28: 216–222. 26 Kalmijn, S., L.J. Launer, A. Ott, J.C.M. Witteman, A. Hofman & M.M.B. Breteler. 1999. Dietary fat intake and the risk of dementia in a population-based study: the Rotterdam Study. Ann. Neurol. 42: 776–782. 27 McGeer, P.L. & E.G. McGeer. 1995. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Rev. 21: 195–218. 28 Eikelenboom, P. & R. Veerhuis. 1996. The role of complement and activated microglia in the pathogenesis of Alzheimer's disease. Neurobiol. Aging 17: 673–680. 29 Thomas, T., M. Mullan, et al. 1996. beta-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 380: 168–171. 30 Andersen, K., L.J. Launer, A. Ott, A.W. HOES, M.M.B. Breteler & A. Hofman. 1995. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study. Neurology 45: 1441–1445. 31 In 'T Veld, B.A., L.J. Launer, A.A.W. Hoes, A. Ott, A. Hofman, M.M.B. Breteler & B.H.C. Stricker. 1998. NSAIDs and incident Alzheimer's disease: the Rotterdam Study. Neurobiol. Aging 19: 607–611. 32 De Groot, J.C., F.E. de Leeuw & M.M.B. Breteler. 1998. Cognitive correlates of cerebral white matter changes. J. Neural Transm. Suppl. 53: 41–67. 33 Bots, M.L., J.C. van Swieten, M.M.B. Breteler, P.T.V.M. de Jong, J. van Gijn, A. Hofman & D.E. Grobbee. 1993. Cerebral white matter lesions and atherosclerosis in the Rotterdam Study. Lancet 341: 1232–1237. 34 Breteler, M.M.B., N.M. van Amerongen, J.C. van Swieten, J.J. Claus, D.E. Grobbee, J. van Gijn, A. Hofman & F. van Harskamp. 1994. Cognitive correlates of ventricular enlargement and cerebral white matter lesions on MRI: the Rotterdam Study. Stroke 25: 1109–1115. 35 De Leeuw, F.E., J.C. de Groot, M. Oudkerk, J.C.M. Witteman, A. Hofman, J. van Gijn & M.M.B. Breteler. 1999. A follow-up study of blood pressure and cerebral white matter lesions. Ann. Neurol. 46: 827–833. 36 De Groot, J.C., F.E. de Leeuw, M. Oudkerk, J. van Gijn, A. Hofman, J. Jolles & M.M.B. Breteler. 2000. Cerebral white matter lesions and cognitive function: the Rotterdam Scan Study. Ann. Neurol. 47: 145–151. Citing Literature Volume903, Issue1VASCULAR FACTORS IN ALZHEIMER'S DISEASEApril 2000Pages 457-465 ReferencesRelatedInformation
Publication Year: 2000
Publication Date: 2000-04-01
Language: en
Type: article
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 228
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot